{"id":2730,"date":"2011-12-01T17:30:33","date_gmt":"2011-12-01T16:30:33","guid":{"rendered":"https:\/\/www.rcts.fr\/uncategorized\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study"},"modified":"2020-04-07T16:11:21","modified_gmt":"2020-04-07T14:11:21","slug":"primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study","status":"publish","type":"post","link":"https:\/\/www.rcts.fr\/en\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\/","title":{"rendered":"Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study"},"content":{"rendered":"

J Clin Oncol 29: 2011 (suppl. abstr 531) – 2011 ASCO Annual Meeting<\/span><\/p>\n

P. Viens, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. Roch\u00e9, M. Pavlyuk, T.D. Bachelot, E. Charafe-Joffret<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

J Clin Oncol 29: 2011 (suppl. abstr 531) – 2011 ASCO Annual Meeting P. Viens, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. Roch\u00e9, M. Pavlyuk, T.D. Bachelot, E. Charafe-Joffret<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false},"categories":[63],"class_list":["post-2730","post","type-post","status-publish","format-standard","hentry","category-oncology"],"acf":[],"yoast_head":"\nPrimary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study - RCTs<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/www.rcts.fr\/en\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study - RCTs\" \/>\n<meta property=\"og:description\" content=\"J Clin Oncol 29: 2011 (suppl. abstr 531) – 2011 ASCO Annual Meeting P. Viens, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. Roch\u00e9, M. Pavlyuk, T.D. Bachelot, E. Charafe-Joffret\" \/>\n<meta property=\"og:url\" content=\"http:\/\/www.rcts.fr\/en\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\/\" \/>\n<meta property=\"og:site_name\" content=\"RCTs\" \/>\n<meta property=\"article:published_time\" content=\"2011-12-01T16:30:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-07T14:11:21+00:00\" \/>\n<meta name=\"author\" content=\"Didier Not\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Didier Not\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\\\/#article\",\"isPartOf\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\\\/\"},\"author\":{\"name\":\"Didier Not\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\"},\"headline\":\"Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study\",\"datePublished\":\"2011-12-01T16:30:33+00:00\",\"dateModified\":\"2020-04-07T14:11:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\\\/\"},\"wordCount\":60,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\"},\"articleSection\":[\"Oncology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\\\/\",\"url\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\\\/\",\"name\":\"Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study - RCTs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#website\"},\"datePublished\":\"2011-12-01T16:30:33+00:00\",\"dateModified\":\"2020-04-07T14:11:21+00:00\",\"breadcrumb\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\\\/\\\/www.rcts.fr\\\/en\\\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/\",\"name\":\"RCTs\",\"description\":\"Description\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rcts.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\",\"name\":\"RCTs\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"contentUrl\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"width\":163,\"height\":47,\"caption\":\"RCTs\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\",\"name\":\"Didier Not\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"caption\":\"Didier Not\"},\"url\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/author\\\/dnorcts-fr\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study - RCTs","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/www.rcts.fr\/en\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\/","og_locale":"en_US","og_type":"article","og_title":"Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study - RCTs","og_description":"J Clin Oncol 29: 2011 (suppl. abstr 531) – 2011 ASCO Annual Meeting P. Viens, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. Roch\u00e9, M. Pavlyuk, T.D. Bachelot, E. Charafe-Joffret","og_url":"http:\/\/www.rcts.fr\/en\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\/","og_site_name":"RCTs","article_published_time":"2011-12-01T16:30:33+00:00","article_modified_time":"2020-04-07T14:11:21+00:00","author":"Didier Not","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Didier Not"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"http:\/\/www.rcts.fr\/en\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\/#article","isPartOf":{"@id":"http:\/\/www.rcts.fr\/en\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\/"},"author":{"name":"Didier Not","@id":"https:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5"},"headline":"Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study","datePublished":"2011-12-01T16:30:33+00:00","dateModified":"2020-04-07T14:11:21+00:00","mainEntityOfPage":{"@id":"http:\/\/www.rcts.fr\/en\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\/"},"wordCount":60,"commentCount":0,"publisher":{"@id":"https:\/\/www.rcts.fr\/#organization"},"articleSection":["Oncology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"http:\/\/www.rcts.fr\/en\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\/","url":"http:\/\/www.rcts.fr\/en\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\/","name":"Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study - RCTs","isPartOf":{"@id":"https:\/\/www.rcts.fr\/#website"},"datePublished":"2011-12-01T16:30:33+00:00","dateModified":"2020-04-07T14:11:21+00:00","breadcrumb":{"@id":"http:\/\/www.rcts.fr\/en\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/www.rcts.fr\/en\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/www.rcts.fr\/en\/primary-efficacy-analysis-of-a-phase-ii-study-of-neoadjuvant-bevacizumab-bev-chemotherapy-ct-and-trastuzumab-h-in-her2-positive-inflammatory-breast-cancer-ibc-beberly2-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rcts.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT) and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEBERLY2 study"}]},{"@type":"WebSite","@id":"https:\/\/www.rcts.fr\/#website","url":"https:\/\/www.rcts.fr\/","name":"RCTs","description":"Description","publisher":{"@id":"https:\/\/www.rcts.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rcts.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rcts.fr\/#organization","name":"RCTs","url":"https:\/\/www.rcts.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rcts.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","contentUrl":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","width":163,"height":47,"caption":"RCTs"},"image":{"@id":"https:\/\/www.rcts.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5","name":"Didier Not","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","caption":"Didier Not"},"url":"https:\/\/www.rcts.fr\/en\/author\/dnorcts-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/comments?post=2730"}],"version-history":[{"count":1,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2730\/revisions"}],"predecessor-version":[{"id":2733,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2730\/revisions\/2733"}],"wp:attachment":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/media?parent=2730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/categories?post=2730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}